Jianda Biomedical Secures Nearly RMB 100 Million in Pre-A Funding to Advance Innovative Adjuvant-Based Zoster Vaccine into Clinical Trials

VCBeat has learned that the pioneer in innovative vaccine and novel adjuvant R&D—Jianda Biopharmaceuticals (Nanjing) Co., Ltd.(hereinafter referred to as “Jianda Bio”) announced the completion of a financing round led byHyfinity InvestmentsAn exclusive investment of nearly RMB 100 million in the Pre-A financing round.

The proceeds from this round of financing will be used to conduct Phase I–II clinical trials for an innovative adjuvanted herpes zoster vaccine, submit clinical trial applications for a recombinant influenza vaccine, and expand the construction of related technology platforms.

Jianda Biologics is a clinical-stage innovative vaccine developer founded by an elite team of experts in vaccine research and development, industrialization, and commercialization from both China and abroad. Its scientific advisory board includes members of the U.S. National Academy of Sciences, internationally renowned Chinese virology experts, and leading scholars in the field of vaccinology in China. Driven by proprietary innovative technologies, the company focuses on the development of novel vaccines and new adjuvants, and has established its own intellectual property-protected platforms for novel adjuvants and dendritic cell (DC)-targeting vaccines.

Currently, a series of projects—including an innovative adjuvanted zoster vaccine, a recombinant influenza vaccine, an improved two-dose rabies vaccine, and therapeutic cancer vaccines—are at various stages, including clinical trials, Investigational New Drug (IND) filings in China and the United States, and pilot-scale production.

Jianda Biologics is dedicated to addressing unmet clinical needs, leveraging its technological advantages across the entire vaccine industry chain, as demonstrated in the following areas:

• Internationally leading CpG innovative adjuvants, traditional aluminum adjuvants, and MF59.

• The pipeline projects include multiple vaccines for the prevention of major infectious diseases and therapeutic cancer vaccines.

• Recombinant Expression Technology Platforms for Diverse Vaccine Types (CHO Cells, Insect Cells, Yeast, and E. coli)

• Fully independent development capabilities (antigen design, sequence optimization, upstream and downstream processes and analytical methods, formulation screening and optimization).

• Comprehensive safety evaluation study design, with IND submission experience.

• Extensive clinical trial experience (Phase I–III).

• Commercialized GMP Manufacturing Processes and Proven Success in Industrial Scale-up.

Dr. Ming Zhou, Founder of Jianda BiotechStated: “We appreciate Hyfinity Investments’ recognition and support for Jianda Biologics and its team, which will significantly accelerate the development of our first-in-class and best-in-class innovative vaccines. While expediting clinical studies, the Company will establish multiple new first-in-class pipelines and actively engage with strategic partners to maximize pipeline value.”

Dr. He Xin, Managing Partner at Hyfinity InvestmentsHyfinity Investments stated: “We are delighted to have the opportunity to support Jianda Bio’s development through this round of investment. Focusing on the R&D of innovative vaccines and novel adjuvants, Jianda Bio has developed an adjuvant platform that balances safety and efficacy, as well as innovative vaccine candidates with best-in-class potential, all driven by unmet clinical needs. Amidst the current challenges facing China’s biopharmaceutical industry, Jianda Bio’s innovation capabilities, the team’s solid expertise and execution strength, and its outstanding data strongly demonstrate the company’s value and growth potential. Committed to supporting enterprises with global technological innovations, Hyfinity Investments is highly optimistic about Jianda Bio’s future R&D progress and clinical advancement, and looks forward to providing robust post-investment support to facilitate the company’s greater development.”

Hyfinity Investments brings together a team of senior partners from China’s leading investment institutions, leveraging years of entrepreneurial and operational experience, expertise in localizing overseas technologies in China, and strong capabilities in building industry resources. Committed to integrating global technological innovations and focusing on the upgrading of China’s healthcare industry, Hyfinity empowers enterprise growth by capitalizing on its extensive clinical and industry resources accumulated over the years. The firm strategically focuses on high-growth, high-barrier sectors such as immunotherapy, regenerative medicine, and precision medicine, pooling resources to strongly support Chinese enterprises in becoming industry leaders.